Physician profile
Abigail M Hamilton
NPI 1790321693
$13,575.36
in general payments reported to CMS, 2019-2025
27 companies · $3,219 in 2025
The $3,219 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,529 · 2022: $2,177 · 2023: $3,454 · 2024: $3,196 · 2025: $3,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,787 · Education: $82.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,787.09 |
| Education | $82.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,660.15 | 2021-2025 | Caplyta |
| Abbvie INC. | $2,323.48 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,570.02 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $1,169.13 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $934.37 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $773.95 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $693.09 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $629.57 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $584.28 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $387.07 | 2022-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $351.72 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $325.93 | 2021-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $240.54 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $212.16 | 2022-2025 | Rexulti |
| Revance Therapeutics, INC. | $146.44 | 2025 | Daxxify |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $117.56 | 2023-2025 | Sublocade, Perseris |
| Braeburn INC. | $89.21 | 2024-2025 | Brixadi |
| Corium, LLC | $85.29 | 2022-2025 | Azstarys |
| Merz North America, INC. | $66.82 | 2021-2022 | |
| Noven Therapeutics, LLC | $39.86 | 2025 | Secuado, Xelstrym |
| Sunovion Pharmaceuticals INC. | $39.80 | 2021 | |
| Atricure, INC. | $34.77 | 2023 | |
| Jazz Pharmaceuticals INC. | $27.57 | 2022 | |
| Viiv Healthcare Company | $26.17 | 2022 | |
| Neos Therapeutics, LP | $16.89 | 2021 | |
| Orexo US, INC. | $16.45 | 2025 | Zubsolv |
| Galderma Laboratories, L.P. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.